Jove
Visualize
Contact Us
JoVE
x logofacebook logolinkedin logoyoutube logo
ABOUT JoVE
OverviewLeadershipBlogJoVE Help Center
AUTHORS
Publishing ProcessEditorial BoardScope & PoliciesPeer ReviewFAQSubmit
LIBRARIANS
TestimonialsSubscriptionsAccessResourcesLibrary Advisory BoardFAQ
RESEARCH
JoVE JournalMethods CollectionsJoVE Encyclopedia of ExperimentsArchive
EDUCATION
JoVE CoreJoVE BusinessJoVE Science EducationJoVE Lab ManualFaculty Resource CenterFaculty Site
Terms & Conditions of Use
Privacy Policy
Policies

Related Concept Videos

Differentiation of Common Myeloid Progenitor Cells01:15

Differentiation of Common Myeloid Progenitor Cells

3.6K
Common myeloid progenitors (CMPs) are oligopotent cells that can differentiate into granulocytes and macrophages. Granulocytes and macrophages are essential for protecting the body against bacterial, viral, or fungal infections. They migrate from the bone marrow into the circulating blood to reach specific tissue sites where they differentiate and help in immune surveillance. However, they survive only for a few days and must be continuously made available to the organism to maintain a robust...
3.6K
Stem Cell Therapy for Tissue Regeneration01:21

Stem Cell Therapy for Tissue Regeneration

4.4K
Stem cell therapy is a method used in regenerative medicine to repair and restore function to damaged tissues and organs. Stem cells have the potential to proliferate and differentiate into various tissue types, making them ideal candidates for tissue regeneration. For example, hematopoietic stem cell transplants are commonly used in blood cancer treatment to replenish damaged bone marrow and restore healthy blood cells.
Types of Stem Cells used in Stem Cell Therapy
The two main cell...
4.4K

You might also read

Related Articles

Articles linked to this work by shared authors, journal, and citation graph.

Sort by
Same author

Matched unrelated vs haploidentical donor hematopoietic cell transplantation using posttransplant cyclophosphamide.

Blood advances·2025
Same author

Real-world outcomes of infections following tisagenlecleucel in patients with B-cell ALL: a CIBMTR analysis.

Blood advances·2025
Same author

Randomized phase 2 study to assess the role of single-agent nivolumab to maintain remission in acute myeloid leukemia.

Blood advances·2025
Same author

Socioeconomic determinants of the biology and outcomes of acute lymphoblastic leukemia in adults.

Blood advances·2023
Same author

Post-transplantation cyclophosphamide is associated with increased bacterial infections.

Bone marrow transplantation·2023
Same author

Allogeneic hematopoietic cell transplantation for blastic plasmacytoid dendritic cell neoplasm: a CIBMTR analysis.

Blood advances·2023
Same journal

Dual-modular-nanobody CAR-T cell technical platform against the solid tumor microenvironment.

Journal of hematology & oncology·2026
Same journal

KRAS inhibition is an effective therapy for appendiceal adenocarcinoma.

Journal of hematology & oncology·2026
Same journal

Short ramp-up glofitamab halves mortality risk after anti-CD19 CAR T-cell therapy failure in patients with diffuse large B-cell lymphoma: final results of the LYSA BiCAR phase 2 trial with a pre-specified external control arm.

Journal of hematology & oncology·2026
Same journal

Large language model-guided CAR-T in silico platform for cytokine optimization in liver cancer with low antigen density.

Journal of hematology & oncology·2026
Same journal

Long-term control of peritoneal metastases following claudin 18.2-targeted CAR T-Cell therapy in advanced gastric cancer.

Journal of hematology & oncology·2026
Same journal

Vibecotamab for measurable residual disease in acute myeloid leukemia and for myelodysplastic syndromes and chronic myelomonocytic leukemia after hypomethylating agent failure: a phase II study.

Journal of hematology & oncology·2026
See all related articles

Related Experiment Video

Updated: Nov 11, 2025

Comprehensive Protocol to Sample and Process Bone Marrow for Measuring Measurable Residual Disease and Leukemic Stem Cells in Acute Myeloid Leukemia
09:57

Comprehensive Protocol to Sample and Process Bone Marrow for Measuring Measurable Residual Disease and Leukemic Stem Cells in Acute Myeloid Leukemia

Published on: March 5, 2018

29.9K

Emerging agents and regimens for AML.

Hongtao Liu1

  • 1Section of Hematology/Oncology, Department of Medicine, The University of Chicago Medical Center, 5841 S. Maryland Ave, MC 2115, Chicago, IL, 60637-1470, USA. hliu2@medicine.bsd.uchicago.edu.

Journal of Hematology & Oncology
|March 24, 2021
PubMed
Summary
This summary is machine-generated.

Recent advances in acute myeloid leukemia (AML) treatment have expanded options beyond traditional chemotherapy. New targeted therapies and immunotherapies are improving survival for AML patients.

Keywords:
AMLNovel treatmentTargeted therapy

More Related Videos

Intracellular Phosphoflow Cytometry of Acute Myeloid Leukemia Patient-Derived Xenotransplants
07:38

Intracellular Phosphoflow Cytometry of Acute Myeloid Leukemia Patient-Derived Xenotransplants

Published on: June 6, 2025

428
Flow Cytometry to Estimate Leukemia Stem Cells in Primary Acute Myeloid Leukemia and in Patient-derived-xenografts, at Diagnosis and Follow Up
09:01

Flow Cytometry to Estimate Leukemia Stem Cells in Primary Acute Myeloid Leukemia and in Patient-derived-xenografts, at Diagnosis and Follow Up

Published on: March 26, 2018

14.3K

Related Experiment Videos

Last Updated: Nov 11, 2025

Comprehensive Protocol to Sample and Process Bone Marrow for Measuring Measurable Residual Disease and Leukemic Stem Cells in Acute Myeloid Leukemia
09:57

Comprehensive Protocol to Sample and Process Bone Marrow for Measuring Measurable Residual Disease and Leukemic Stem Cells in Acute Myeloid Leukemia

Published on: March 5, 2018

29.9K
Intracellular Phosphoflow Cytometry of Acute Myeloid Leukemia Patient-Derived Xenotransplants
07:38

Intracellular Phosphoflow Cytometry of Acute Myeloid Leukemia Patient-Derived Xenotransplants

Published on: June 6, 2025

428
Flow Cytometry to Estimate Leukemia Stem Cells in Primary Acute Myeloid Leukemia and in Patient-derived-xenografts, at Diagnosis and Follow Up
09:01

Flow Cytometry to Estimate Leukemia Stem Cells in Primary Acute Myeloid Leukemia and in Patient-derived-xenografts, at Diagnosis and Follow Up

Published on: March 26, 2018

14.3K

Area of Science:

  • Hematology
  • Oncology
  • Genomics

Background:

  • Acute myeloid leukemia (AML) treatment historically relied on intensive chemotherapy (cytarabine + anthracycline) and hypomethylating agents.
  • Allogeneic stem cell transplantation (Allo-SCT) has been a key survival-improving strategy for eligible AML patients.
  • Limited therapeutic options previously characterized AML management.

Purpose of the Study:

  • To summarize recent breakthroughs and FDA-approved treatments in acute myeloid leukemia.
  • To review the expansion of therapeutic options driven by genomic and molecular understanding of AML.
  • To discuss the potential of emerging immunotherapies for AML treatment.

Main Methods:

  • Review of recent translational research in AML.
  • Analysis of genomic and molecular landscape of AML.
  • Evaluation of novel therapeutic agents and immunotherapies.

Main Results:

  • Significant expansion of AML treatment options due to molecular insights.
  • Development of targeted therapies and combination treatments overcoming resistance.
  • FDA approvals for new therapeutic strategies in AML.

Conclusions:

  • Advances in understanding AML pathogenesis have rapidly expanded treatment choices.
  • Targeted therapies and immunotherapy represent promising avenues for improved AML patient survival.
  • The therapeutic armamentarium for AML continues to grow, offering new hope.